Time to all-cause treatment discontinuation as the primary outcome in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia study

Statistics in Biopharmaceutical Research

Volumn 3, Issue 2, 2011, Pages 253-265

  Davis, Sonia M ^a   Stroup, T Scott ^b   Koch, Gary G ^c   Davis, Clarence E ^c   Rosenheck, Robert A ^d   Lieberman, Jeffrey A ^b  

^a IQVIA   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drop out; Graphical response profiles; Informative missing data; Lost to follow up; Treatment failure

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; KAPLAN MEIER METHOD; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SHORT FORM 12; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

EID: 80052497554     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1198/sbr.2011.10013     Document Type: Article

References (19)

1. Alison, P. (2010), Survival Analysis Using the SAS System: A Practical Guide (2nd ed.), Cary, NC: SAS Institute, Inc. 263
2. Cheng, Y., Fine, J. P., and Kosorok, M. R. (2007), "Nonparametric Association Analysis of Bivariate Competing Risks Data, " Journal of American Statistical Association, 102, 1407-1415. 263
3. Cox, D. (1972), "Regression Models and Life Tables, " Journal of the Royal Statistical Society, Ser. B, 34, 187-220. 254
4. Davis, S. M., Koch, G. G., Davis, C. E., and LaVange, L. M. (2003), "Statistical Approaches to Effectiveness Measurement and Outcome-Driven Rerandomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Studies, " Schizophrenia Bulletin, 29, 73-80. 254
5. Gueorguieva, R., Rosenheck, R., and Lin, H. (2011) "Joint Modeling of Longitudinal Outcome and Interval-censored Competing Risk Dropout in a Schizophrenia Clinical Trial, " Journal of the Royal Statistical Society, Ser. A, in press. 255
6. Heinrichs, D. W., Hanlon, T. E., and Carpenter, W. T. (1984), "The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome, " Schizophrenia Bulletin, 10, 388-398. 256
7. Henderson, R., Diggle, P., and Dobson, A. (2000), "Joint Modeling of Longitudinal Measurements and Event Time Data, " Biostatistics, 4, 465-480. 255
8. Hogan, J.W., and Laird, N.M. (1997), "Mixture Models for the Joint Distributions of Repeated Measures and Event Times, " Statistics in Medicine, 16, 239-257. 255
9. Hung, H.M. J. (2004), "Management of Missing Data in Clinical Trials from a Regulatory Perspective, " presented at American Statistical Association Biopharmaceutical section FDA/Industry Workshop. 255
10. Kraemer, H. C., Glick, I. D., and Klein, D. F. (2009), "Clinical Trials Design Lessons from the CATIE Study, " American Journal of Psychiatry, 166, 1222-1228. 263
11. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., and Hsiao, J. K. for the CATIE investigators (2005), "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia, " New England Journal of Medicine, 353, 1209-1223. 253, 254, 256, 262
12. Little, R. J. A. (1993), "Pattern-Mixture Models for Multivariate Incomplete Data, " Journal ofthe American Statistical Association, 88, 125-134. 255
13. McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., Severe, J., and Hsiao, J.K., for CATIE Investigators (2006), "Effectiveness of Clozapine versus Olanzapine, Quetiapine and Risperidone in Patients with Chronic Schizophrenia who did not Respond to Prior Atypical Antipsychotic Treatment, " American Journal of Psychiatry, 163, 600-610. 256
14. Ohidul, S., Hung, H. M. J., and O'Neill, R. (2009), "MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets, " Journal of Biopharmaceutical Statistics, 19, 227-246. 255
15. Peng, L., and Fine, J., P. (2007), "Regression Modeling of Semicompeting Risks Data, " Biometrics, 63, 96-108. 263
16. Saville, B. R., Herring, A. H., and Koch, G. G. (2010), "A Robust Method for Comparing Two Treatments in a Confirmatory Clinical Trial via Multivariate Time-to-Event Methods that Jointly Incorporate Information from Longitudinal and Time-to-Event Data, " Statistics in Medicine, 29 75-85. 255
17. Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, C.D., Severe, J., and Hsiao, J. K., for the CATIE Investigators (2006), "Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients with Chronic Schizophrenia After Discontinuing a Previous Atypical Antipsychotic, " American Journal of Psychiatry, 163, 611-622. 256
18. Stroup, T. S., Lieberman, J. A, McEvoy, J. P., Swartz, M. S., Davis, S. M., Capuano, G., Rosenheck, R. A., Keefe, R. S. E., Miller, A., Belz, I., and Hsiao, J. K. for the CATIE Investigators (2007), "Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients with Chronic Schizophrenia after Discontinuing Perphenazine: A CATIE Study, " American Journal of Psychiatry, 164, 415-427. 256
19. Wulfsohn, M. S., and Tsiatis, A. A. (1997), "A Joint Model for Survival and Longitudinal Data Measured with Error, " Biometrics, 53, 330-339. 255